Organ transplantation is the measure of last resort for patients with organ failure. While this is a life-saving procedure, the long-term survival of transplant recipients depends on maintaining the new organ without rejecting it. The proposed research will create novel test systems that allow both patients and clinicians to monitor the concentration of the drugs required to suppress organ rejection. Such a test will reduce the cost of treatment and increase the long term survival of patients.
A portable device that can measure glycosylated haemoglobin (HbA1c) in the home will be developed. HbA1c is an important biomarker of the average blood glucose levels over the preceding three months and hence guides a diabetic regarding their blood glucose treatment regime. A 1% decrease in HbA1c levels is associated with a dramatic decrease in chronic health complications from diabetes. The HbA1c meter that will be developed will be able to operate with existing glucose meter technologies.